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Abstract The ADAM family of proteases are type I trans-
membrane proteins with both metalloproteinase and disintegrin
containing extracellular domains. ADAMs are implicated in the
proteolytic processing of membrane-bound precursors and in-
volved in modulating cell^cell and cell^matrix interactions.
ADAM8 (MS2, CD156) has been identi¢ed in myeloid and B
cells. In this report we demonstrate that soluble ADAM8 is an
active metalloprotease in vitro and is able to hydrolyse myelin
basic protein and a variety of peptide substrates based on the
cleavage sites of membrane-bound cytokines, growth factors and
receptors which are known to be processed by metalloprotei-
nases. Interestingly, although ADAM8 was inhibited by a num-
ber of peptide analogue hydroxamate inhibitors, it was not in-
hibited by the tissue inhibitors of metalloproteinases (TIMPs).
We also demonstrate that the activity of recombinant soluble
ADAM9 (meltrin-Q, MDC9) lacks inhibition by the TIMPs, but
can be inhibited by hydroxamate inhibitors. The lack of TIMP
inhibition of ADAM8 and 9 contrasts with other membrane-
associated metalloproteinases characterised to date in this re-
spect (ADAM10, 12, 17, and the membrane-type metalloprotei-
nases) which have been implicated in protein processing at the
cell surface. 1 2002 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The ADAMs are a recently discovered family of membrane-
anchored metalloproteinases with a complex domain structure
including a metalloproteinase, disintegrin, cysteine-rich, trans-
membrane and cytoplasmic domains [1]. About half of the 33
ADAMs cloned to date are predicted to be active metallopro-
teinases based on the presence of the HEXXH zinc binding
motif. Of these, ADAM17, or tumour necrosis factor-K
(TNFK) converting enzyme (TACE), is the most thoroughly
characterised member. In addition to processing precursor
membrane-bound TNFK to its soluble form, TACE also
cleaves other membrane proteins [2]. Some of the ADAMs
predicted to be active metalloproteinases have also subse-
quently been demonstrated to be able to participate in similar
proteolytic activities as TACE in vitro in cell-based systems
[1]. The catalytic activities of puri¢ed recombinant ADAMs
have been studied using the in vitro proteins K2-macroglobu-
lin and myelin basic protein (MBP) as well as various peptides
[3^6]. These assays have allowed their susceptibility towards
the tissue inhibitors matrix metalloproteinases (TIMPs), po-
tential physiological regulators of ADAM proteolytic activity
in vivo, to be evaluated, as well as many low molecular weight
synthetic inhibitors. Four di¡erent TIMPs have been identi-
¢ed so far, but only TIMP-3 was found to inhibit TACE and
ADAM12 [7,8], whilst both TIMP-1 and TIMP-3 could in-
hibit ADAM10 [3]. Furthermore, TIMP-3 also inhibited the
aggrecanases ADAMTS-4 and ADAMTS-5, which are mem-
bers of the related family of disintegrin metalloproteinases
with thrombospondin domains [9,10]. This contrasts with
the membrane-type metalloproteinases (MT-MMPs) which
are inhibited by TIMP-2, 3 and 4 (e.g. MT1-MMP) or
TIMP-1, 2, 3 and 4 (e.g. MT4-MMP) [11,12], W. English
and V. Kna«uper, unpublished observations). There is some
evidence that the MT-MMPs may also participate in proteo-
lytic processing of membrane-anchored proteins [11,13,14].
Characterising the TIMP inhibition pro¢le of the remaining
proteolytically active ADAMs will increase their usefulness as
tools in the identi¢cation of metalloproteinases involved in
cellular events, aid in determining their potential as therapeu-
tic agents and explain consequences of TIMP activity such as
TIMP-3’s ability to promote apoptosis in certain cell types
[15,16].
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Here, we have extended the study of TIMP susceptibility to
ADAM8 and 9. ADAM8 was further characterised to evalu-
ate its catalytic properties in comparison to those of other
ADAMs and the MT-MMPs.
2. Material and methods
2.1. Materials and general procedures
Protein A and soybean trypsin inhibitor-conjugated Sepharose and
all other non-speci¢ed reagents were from Sigma (Poole, UK). Re-
combinant enterokinase was from Novagen (Cambridge Bioscience,
Cambridge, UK). Recombinant human TIMPs-1, -2 and -3 were ex-
pressed in NS0 (non-secreter zero) mouse myeloma cells and puri¢ed
as previously described [17]. Full-length mouse TIMP-4 was expressed
and refolded from Escherichia coli (V. Kna«uper, unpublished). Re-
combinant human MT1-MMP ectodomain and the catalytic domain
of mouse MT4-MMP were prepared as described previously [11,12].
ADAM9 and ADAM17 were prepared as described previously [6,7].
The peptides Ac-LPPVAASSLR-NH2 (KL1), Ac-KENSFEMQK-
GAQ-NH2 (CD40L), Ac-TVKEASSTFSWG-NH2 (IL1R) and Ac-
GLSLPVENRLYTYD-NH2 (HB-EGF) are based on the respective
cleavage sites for the TNF-related cytokine c-kit ligand-1 (KL1),
CD40 ligand, the interleukin-1 receptor (IL-1R), and heparin binding
epidermal growth factor (HB-EGF). These peptides were a kind gift
from R. Black, Immunex (Seattle, WA, USA). The APP (H-
YEVHHQKLVFF-OH) and MBP (H-YGSLPQKAQRPQDEN-OH)
peptide fragments were from Bachem (Bubendorf, Switzerland). The
TNF-based peptide was as previously published [7].
High performance liquid chromatography (HPLC) analyses were
performed on a Perkin-Elmer Integral 4000 instrument equipped
with a Vydac 218TP54 column maintained at 40‡C. Solvents were:
A, 0.1% tri£uoroacetic acid (TFA) in water; B, 0.08% TFA in aceto-
nitrile. A linear gradient from 5 to 95% B was run over 20 min at 1.25
ml/min and the eluate was monitored at 230 nm. Electrospray mass
analysis of the peptide fragments was conducted as previously de-
scribed [7].
N-terminal sequencing was done by electrophoretically transferring
5 Wg of puri¢ed protein onto a polyvinylidene di£uoride membrane
(Immobilon P, Millipore), which was then stained with Ponceau red
and washed extensively with distilled water. The band corresponding
to the protein was excised for sequencing using an Applied Biosystems
470 microsequencer [3].
2.2. Expression and puri¢cation of recombinant ADAM8
A full-length cDNA for murine ADAM8 was isolated essentially as
previously described for ADAM17 [7]. The DNA fragment encoding
the prepro-catalytic domain was ampli¢ed by PCR and ligated into
the vector pEE12 such that it was joined at a SalI site to a sequence
encoding an enterokinase cleavage site ([V405 in ADAM8V]DDDDKs)
followed by the human IgG1 heavy chain constant region, hinge,
CH2 and CH3 domains. The vector was transfected into mouse
NS0 myeloma cells and clones expressing soluble recombinant protein
were used as a source of conditioned media for puri¢cation of the
ADAM8 catalytic domain as described for ADAM17 [7]. Brie£y,
100 ml of conditioned medium was treated with 0.5 ml of protein
A-Sepharose. The gel was washed and ADAM8 was eluted by speci¢c
cleavage at the enterokinase cleavage site using 20 U of recombinant
enterokinase. The enterokinase was removed with soybean trypsin
inhibitor-Sepharose and the eluted protein was analysed by sodium
dodecyl sulphate^polyacrylamide gel electrophoresis (SDS^PAGE)
(10% polyacrylamide) under reducing conditions and by N-terminal
sequencing.
2.3. Enzyme assays
ADAM8 (5 Wg/ml) was incubated at 37‡C with MBP (500 Wg/ml)
and peptides (50 WM) in 10 mM HEPES, 0.05% Brij-35 (v/v), pH 7.5.
MBP and enzyme incubation mixtures were analysed by 14% SDS^
PAGE under reduced conditions. Peptide cleavage reactions were
stopped at di¡erent times by dropping the pH to 4. The samples
(100 Wl) were then analysed by HPLC. Comparative analysis of the
cleavage patterns produced by MT-MMPs was conducted at 25‡C.
The fragment peaks were collected and identi¢ed by mass spectrom-
etry. The percentage of peptide cleavage was calculated on the basis of
the peak areas of start and end products from absorbance monitored
at 220 nm. Activity of ADAM9 in 20 mM HEPES, 0.01% Triton
X-100 (v/v), pH 7.5 was monitored by following hydrolysis of the
quenched £uorescent TNFK-based peptide essentially as described in
[7]. The concentration of ADAM9 was estimated by active site titra-
tion with the hydroxamate inhibitor CGS27023 (GlaxoSmithKline,
Stevenage, UK) or BB94 (British Biotech, Oxford, UK). Inhibition
by TIMP-1, 2 and 3 was followed as described in [7] by pre-incubation
of 8 nM ADAM9 with TIMP at concentrations from 1 nM to 0.2 WM
for 16 h prior to the addition of the TNFK peptide substrate.
3. Results and discussion
3.1. Puri¢cation of ADAM8
Recombinant ADAM8 catalytic domain was puri¢ed by
a⁄nity chromatography on protein A-Sepharose and enter-
okinase treatment to remove the C-terminal Fc tag (Fig.
1A). The MW of the resulting protein was 33 kDa by SDS^
PAGE and Coomassie staining (Fig. 1B). N-terminal sequenc-
ing of the puri¢ed material indicated that ADAM8 was pro-
cessed after Arg187, which is situated between the predicted
Fig. 1. SDS^PAGE analysis of puri¢ed ADAM8. A: Schematic rep-
resentation of the ADAM8 prepro-catalytic domain expressed as a
Fc fusion. The arrowheads to the left indicate the propeptide pro-
cessing sites as determined by N-terminal sequencing. The arrow-
head to the right indicates the anticipated cleavage that occurs after
treatment with enterokinase. B: Coomassie-stained SDS^PAGE of
puri¢ed ADAM8. The fusion protein could be bound through the
Fc portion to protein A-Sepharose and free ADAM8 eluted by en-
terokinase cleavage, yielding a protein band at an apparent molecu-
lar weight of 33 kDa. N-terminal sequencing of this protein band
showed that it corresponded to the catalytic domain of ADAM8
lacking the pro-domain.
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propeptide and catalytic domains (Fig. 1A). Thus, the MW
and N-terminal sequence of the puri¢ed material are consis-
tent with it being the ADAM8 catalytic domain from which
the propeptide has been removed.
3.2. MBP degrading activity of ADAM8
To determine whether ADAM8 was catalytically active, the
puri¢ed materials were incubated with MBP and its cleavage
monitored by SDS^PAGE, as previously described [18]. After
a 2-h incubation, the 20-kDa MBP is completely degraded
with the appearance of two prominent protein bands of about
9 and 11 kDa (Fig. 2A). N-terminal sequencing of the 11-kDa
fragment was consistent with cleavage occurring between
Pro73 and Gln74 as previously observed for ADAM10 and
28 [5,18]. MBP was also a good TACE substrate, although
cleavage occurred at Phe42^Phe43 and Phe88^Phe89 [19].
Various proteases have been implicated in MBP degradation
an important feature of demyelinating diseases such as multi-
ple sclerosis (MS) [20]. Although the direct involvement of
ADAMs in demyelination remains to be reported, TACE ex-
pression is increased during experimental allergic encephalo-
myelitis (EAE), an animal model for MS [21], whilst the dis-
integrin domain of ADAM8 had a protective e¡ect on EAE
[22].
3.3. Inhibition of ADAM8 activity
The zinc chelator 1,10-phenanthroline inhibited the MBP
degradation by ADAM8, con¢rming the zinc dependence of
the ADAM8 activity (Fig. 2). Of the four TIMPs, only TIMP-
1 (1 WM) showed slight inhibitory activity after 2 h incubation
time. In contrast, ADAM-10 was fully inhibited by 0.25 WM
of TIMP-1 and 3 under similar conditions [3]. Furthermore,
no additional inhibitory e¡ect was observed at shorter inter-
mediate incubation time points. In a separate assay system, we
Fig. 2. MBP degradation by ADAM8. A: Bovine MBP (500 Wg/ml) was incubated at 37‡C for 4 h with ADAM8 (5 Wg/ml). Reactions were
stopped by the addition of loading bu¡er followed by heating. The protein (5 Wg) was analysed by 14% SDS^PAGE under reduced conditions.
The gel was stained with Coomassie brilliant blue R-250. Lane 1, dimethylsulphoxide. Lane 2, 1 mM 1,10-phenanthroline. Lane 3, 1 WM
TIMP-1. Lane 4, 1 WM TIMP-2. Lane 5, 1 WM TIMP-3. Lane 6, 1 WM TIMP-4. Lane 7, 5 WM CT435. Lane 8, 5 WM CT572. Lane 9, 5 WM
CT635. Lane 10, 5 WM CT1399. Lane 11, 5 WM CT1847. Lane 12, 5 WM CT2256. B: Structures of inhibitors tested on ADAM8.
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also evaluated the ability of the TIMPs to inhibit the soluble
ectodomain of ADAM9 using a quenched £uorescent peptide
based on TNFK. Although ADAM9 was inhibited by hy-
droxamic acid inhibitors CGS27023 and BB94, it was not
inhibited by TIMP-1, 2 or 3 at concentrations up to 200
nM. TIMP-1 was a weak inhibitor of the aggrecanases
ADAMTS-4 and 5 [10], whilst it inhibited ADAM10 well
[3]. This is in contrast to ADAM17 (TACE), which is only
inhibited by TIMP-3 [7], and the MT-MMPs (MT1 by TIMP-
2, 3 and 4, MT4 by TIMP-1, 2, 3 and 4 [11,12] ; W. English
and V. Kna«uper, unpublished observations). In each case
where TIMP inhibition was observed Ki has typically been
estimated to be in the low nM to pM range. We conclude
therefore that the poor potency of the TIMPs towards
ADAM8 and 9 indicates that they do not regulate their pro-
teolytic activity. The varying speci¢city of membrane bound
metalloproteinases towards TIMPs should provide a powerful
tool in the identi¢cation of the type of protease activity ob-
served in cell-based systems (summarised in Table 1).
The MBP degradation assay was also used to carry out
an initial evaluation of the inhibitory potential of various
hydroxamate-based metalloproteinase inhibitors towards
ADAM8. Of the six inhibitors tested, CT435 showed the
most potential as an inhibitor of ADAM8, followed by
CT572 and CT1399 whereas CT635 and CT2256 were poor
ADAM8 inhibitors (Fig. 2A). CT572 and CT1399 have an
extended side chain in P1P (Fig. 2B) indicating that ADAM8
may resemble MMPs such as gelatinase A or collagenase-3
which have a deep S1P speci¢city pocket. At P2P, the cyclo-
hexylmethyl group of CT435, CT572 and CT1399 was pre-
ferred to the smaller isobutyl and tert-butyl groups of CT635
and CT2256, respectively. Taken together these data suggest
that ADAM8 inhibitor potency can be obtained by optimisa-
tion of the P2P and P1P residues.
3.4. Catalytic activity of ADAM8 and towards peptide
substrates
The catalytic activity of ADAM8 towards peptide sub-
strates based on the cleavage region within the juxta-mem-
brane stalk of amyloid precursor protein (APP), TNFK,
CD40 ligand (CD40L), HB-EGF, IL-1R and KL, were com-
pared with two di¡erent members of the MT-MMP family,
MT1 and MT4-MMP (Table 2). These proteins have also
been shown to be able to function as metallosheddases
[11,13], hence it is of interest to compare the speci¢city of
these proteins with those of the ADAMs. This has also al-
lowed us to compare our data with those previously reported
for ADAM9 and 10 ectodomains. ADAM8 was found to
cleave the APP peptide at HsQ, like ADAM9 [6], rather
than at the K-secretase site, KsL, cleaved by ADAM10 [3].
MT4-MMP was found to cleave at both KsL and HsQ,
whereas MT1-MMP was only found to cleave at KsL.
ADAM8 cleavage of the MBP peptide con¢rmed the cleavage
site, PsQ, found within the protein itself. ADAM10 has also
been shown to cleave MBP at this site [3] and although we
found that MT1 and MT4-MMP were able to cleave this
peptide at a single site, we were unable to determine the site
of hydrolysis. On comparison of the cleavage sites found with-
in the TNFK peptide, ADAM8 was found to hydrolyse at two
sites both AsV, as ADAM10 [3] and ADAM17 (TACE, [7])
and AsQ, rather than at QsA like MT4-MMP, or at the two
sites AsQ/SsS (ADAM9, MMP-1, MMP-9 [6]). MT1-MMP
was found to be unable to cleave this peptide. ADAM8 was
able to cleave KL and although MT1 and MT4-MMP were
also able to cleave this peptide, we were unable to identify the
site. This di¡ers from ADAM9, which has been reported to
cleave this peptide at multiple sites [6]. Although we were able
to demonstrate that ADAMs and MT-MMPs were all able to
cleave some peptides in common, albeit with di¡ering speci-
¢city in most cases, we found some instances where more
marked abilities in peptide speci¢city were apparent. For ex-
ample, neither ADAM8 nor ADAM10 were able to cleave the
peptide corresponding to the stalk region of HB-EGF, yet
both MT1-MMP and MT4-MMP were able to hydrolyse
this peptide at PsV/EsN and EsN/RsL respectively.
ADAM8 was able to process the peptide of IL-1R, yet
ADAM10, MT1 and MT4 were unable to do so. We previ-
ously reported that ADAM10 was able to cleave a peptide
based on CD40L [3], yet ADAM8, MT1 and MT4 showed
no activity towards this peptide. It has been proposed that
speci¢city of metallosheddases is governed, in part, by the
amino acid sequence of the peptide in the stalk region of
the shed molecule [23]. Providing these peptides are suitable
mimics of the shed region of the molecule and they are not in
a region containing signi¢cant secondary or tertiary structure,
our comparisons of di¡erent metallosheddase speci¢city indi-
Table 1
Susceptibility pro¢le of putative metallosheddases by TIMP inhibi-
tion
TIMP-1 TIMP-2 TIMP-3 TIMP-4
ADAM8 3 3 3 3
ADAM9 3 3 3 nd
ADAM10a ++ 3 ++ nd
ADAM12b 3 3 + nd
ADAM17c (+) 3 ++ 3
MT1-MMPd 3 ++ ++ ++
MT4-MMPe ++ ++ ++ ++
Data in a^c are from [3,7,8] respectively. Data in d and e are from
[11,12] and W. English and V. Kna«uper, unpublished observations.
3 indicates no inhibition observed at s 1036 M; (+),
10369Kis 1037 M; +, 10376Kis 1038 M; ++, 1038 M6Ki (ap-
proximations from experimental data).
Table 2
Metalloproteinase-mediated cleavage of peptides based on the proteolytically sensitive sequences of shed proteins
Predicted cleavage site ADAM8 ADAM9 ADAM10 MT1-MMP MT4-MMP
CD40L KENSFEsMQKGAQ NC ND MsQ NC NC
HB-EGF GLSLPVEsNRLYTYD NC ND NC PsV+EsN EsN+RsL
IL-1Rc TVKEASsSTFSWG SsS ND NC NC NC
KL LPPVAsAsSSLR AsS SsS+AsS+AsA NC ?s? ?s?
TNFK SPLAQAsVRSSSRK AsQ+AsV AsQ+SsS AsV NC QsA
APP YEVHHQKsLVFF HsQ HsQ KsL KsL KsL+HsQ
MT1 and MT4-MMP cleaved the KL peptide at a single site that could not be identi¢ed, ADAM9 results are from [6].
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cates this could indeed be partly how substrate speci¢city is
regulated. However our study also suggests that it is not
merely the P1 and P1P which in£uence this but also the sur-
rounding amino acids, suggesting these enzymes recognise a
wider ‘footprint’.
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